GSK and Medicago announce partnership to develop novel adjuvanted Covid-19 vaccine

Companies hope to develop and evaluate a COVID-19 candidate vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system. Use of an adjuvant may boost the immune response and reduce the amount of antigen required per dose.

Source:

Biospace Inc.